Do men with mild erectile dysfunction have the same risk factors as the general erectile dysfunction clinical trial population?

BJU International

Volumn 107, Issue 6, 2011, Pages 956-960

  Lee, Jay C ^a   Bénard, Francois ^b   Carrier, Serge ^c   Talwar, Varun ^d   Defoy, Isabelle ^e  

^a Rockyview Hospital   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d Sciformix Technologies Pvt Ltd   (India)

^e PFIZER INC   (United States)

Author keywords

Comorbidity; Demography; Epidemiology; Erectile dysfunction; Risk factors

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTACID AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIULCER AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; SILDENAFIL; TAMSULOSIN; TERAZOSIN;

AGE; ANXIETY DISORDER; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CAUCASIAN; CIGARETTE SMOKING; CLINICAL EVALUATION; COMORBIDITY; DEMOGRAPHY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; EPIDEMIOLOGIC METHODS; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; SULFONES; YOUNG ADULT;

EID: 79952588662     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09691.x     Document Type: Article

References (30)

1. Rosen RC, Fisher WA, Eardley I et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20: 607-17 (Pubitemid 38685004)
2. Tamler R, Bar-Chama N. Assessment of endothelial function in the patient with erectile dysfunction: an opportunity for the urologist. Int J Impot Res 2008; 20: 370-7
3. Elesber AA, Solomon H, Lennon RJ et al. Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J 2006; 27: 824-31
4. El-Sakka AI, Morsy AM, Fagih BI, Nassar AH. Coronary artery risk factors in patients with erectile dysfunction. J Urol 2004; 172: 251-4
5. Ponholzer A, Temml C, Obermayr R, Wehrberger C, Madersbacher S. Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke? Eur Urol 2005; 48: 512-8
6. Schouten BW, Bohnen AM, Bosch JL et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. Int J Impot Res 2008; 20: 92-9
7. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346-51 (Pubitemid 29367263)
8. Fisher WA, Rosen RC, Eardley I et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunction. J Sex Med 2004; 1: 150-60 (Pubitemid 40424648)
9. McCullough AR, Steidle CP, Kaufman J, Goldfischer ER, Klee B, Carlsson M. Sildenafil citrate efficacy 8 h postdose in men with mild to moderate erectile dysfunction. Int J Impot Res 2008; 20: 388-95
10. McCullough AR, Steidle CP, Klee B, Tseng LJ. Randomized, double-blind, crossover trial of sildenafil in men with mild to moderate erectile dysfunction: efficacy at 8 and 12 hours postdose. Urology 2008; 71: 686-92 (Pubitemid 351447298)
11. Tolrà JR, Campaña JM, Ciutat LF, Miranda EF. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006; 3: 901-9 (Pubitemid 44269546)
12. Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J Androl 2007; 9: 134-41 (Pubitemid 46050228)
13. Nagao K, Kimoto Y, Marumo K et al. Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study. Urology 2006; 68: 845-51 (Pubitemid 44633378)
14. Young JM, Feldman RA, Auerbach SM et al. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. J Androl 2005; 26: 310-8 (Pubitemid 40628966)
15. Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res 2005; 17: 307-19 (Pubitemid 41025762)
16. Chang ST, Chu CM, Hsu JT, Lin PC, Shee JJ. Surveillance of cardiovascular risk factors for outpatients in different erectile dysfunction severity. Int J Impot Res 2009; 21: 116-21
17. Chew KK, Bremner A, Jamrozik K, Earle C, Stuckey B. Male erectile dysfunction and cardiovascular disease: is there an intimate nexus? J Sex Med 2008; 5: 928-34 (Pubitemid 351478237)
18. Cho NH, Ahn CW, Park JY et al. Prevalence of erectile dysfunction in Korean men with Type 2 diabetes mellitus. Diabet Med 2006; 23: 198-203
19. El-Sakka AI. Lower urinary tract symptoms in patients with erectile dysfunction: analysis of risk factors. J Sex Med 2006; 3: 144-9
20. El-Sakka AI. Characteristics of erectile dysfunction in Saudi patients. Int J Impot Res 2004; 16: 13-20 (Pubitemid 38401554)
21. Khoo EM, Tan HM, Low WY. Erectile dysfunction and comorbidities in aging men: an urban cross-sectional study in Malaysia. J Sex Med 2008; 5: 2925-34
22. Lu CC, Jiann BP, Sun CC, Lam HC, Chu CH, Lee JK. Association of glycemic control with risk of erectile dysfunction in men with type 2 diabetes. J Sex Med 2009; 6: 1719-28
23. Ponholzer A, Temml C, Mock K, Marszalek M, Obermayr R, Madersbacher S. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005; 47: 80-5
24. Bénard F, Carrier S, Lee JD, Talwar V, Defoy I. Men with mild erectile dysfunction benefit from sildenafil treatment. J Sex Med 2010; [Epub ahead of print]
25. Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010; 64: 240-55
26. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90
27. VIAGRA® (sildenafil citrate). Full Prescribing Information. New York: Pfizer, Inc, 2010. Available at: http://www.pfizer.com/files/products/uspi- viagra.pdf. Accessed September 13 2010
28. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of A WHO Consultation (WHO Technical Report Series 894). Geneva: World Health Organization, 2000
29. 2003 Canadian Community Health Survey. Available at: http://www.statcan. gc.ca/start-debut-eng.html. Accessed September 2009
30. Montorsi F, Briganti A, Salonia A et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44: 360-4